Early Breast Cancer Trialists' Collaborative Group (EBCTCG)(2022-03)
BACKGROUND: For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors are more effective than tamoxifen in ...